Full-Time

Health Outcomes Liaison

Confirmed live in the last 24 hours

Syndax

Syndax

201-500 employees

Develops therapies for difficult-to-treat cancers

No salary listed

Mid, Senior

Boston, MA, USA + 2 more

More locations: Pennsylvania, USA | Concord, NH, USA

Candidates can reside anywhere within the East Region: Massachusetts, Pennsylvania, New Hampshire.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Advanced degree required, preferably M.D., D.O., Pharm.D., Ph.D., APN, or PA.
  • At least 3 years of experience in a Managed Care/PBM, VA/DoD, CMS, State Medicaid, health care consulting, pharmaceutical industry or related environment preferred.
  • Required skills include strong scientific acumen, impactful communication skills, active listening skills, networking, relationship development, lead/influence without authority, business analysis skills, advanced technical expertise and business analysis skills, critical thinking, innovative problem-solving skills and negotiation skills.
Responsibilities
  • Interact with HCPs in the region including therapeutic area HCPs affiliated with organized customers and KOLs within academic and community settings.
  • Respond to medical questions regarding Syndax products for the designated therapeutic area and other Syndax medicines as appropriate.
  • The HOL may be involved in presentations to payers, managed care organizations, formulary decision makers and regional medical advisory boards in accordance with the designated therapeutic area medical strategy.
  • Facilitate communication between regional and national HCPs and headquarters Medical Affairs colleagues, and provide customer insights that contribute to the development of brand medical strategies as appropriate.
  • Facilitate both Syndax sponsored and investigator-initiated studies activities in their regions as determined by the HQ Medical teams and in accordance with guidance.
  • Engage in and develop relationships with KOLs within an assigned territory to discuss data related to Syndax molecules and future pipeline assets.
Desired Qualifications
  • Completion of relevant Residency or Fellowship programs may be considered in lieu of some work experience.
  • Account management experience is preferred.

Syndax Pharmaceuticals develops and commercializes therapies specifically for cancer patients, focusing on challenging cases like hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company conducts research and clinical trials to test the safety and effectiveness of its drugs, with the goal of bringing new treatments to market. Syndax's main product, Entinostat, is currently in clinical trials combined with Exemestane for HR+, HER2- breast cancer. Unlike many competitors, Syndax targets underserved patient populations and relies on strategic partnerships and public offerings to fund its research and development efforts. The company's goal is to advance cancer treatment by developing innovative therapies that address the needs of patients with difficult-to-treat cancers.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of Niktimvo™ positions Syndax uniquely in the chronic GVHD market.
  • Positive AUGMENT-101 trial data enhances Revuforj®'s potential in acute leukemia treatment.
  • Stifel Financial's investment indicates confidence in Syndax's growth and financial stability.

What critics are saying

  • Potential fiduciary breaches could lead to legal challenges and affect investor confidence.
  • Reliance on clinical trial outcomes poses risks if results don't meet expectations.
  • Leadership changes with Dr. Botwood's appointment could disrupt ongoing projects.

What makes Syndax unique

  • Syndax focuses on innovative cancer therapies for difficult-to-treat cancers.
  • The company develops axatilimab, a unique CSF-1 receptor blocker for chronic GVHD.
  • Syndax's entinostat targets HR+, HER2- breast cancer, differentiating it in the oncology market.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

9%

2 year growth

9%
Syndax Pharmaceuticals
May 12th, 2025
Press Release Details

Syndax Pharmaceuticals appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer.

The Manila Times
Apr 2nd, 2025
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Syndax announces participation at the Stifel 2025 Virtual Targeted Oncology Forum.

PR Newswire
Jan 30th, 2025
Syndax Announces Participation In February Investor Conferences

WALTHAM, Mass., Jan. 30, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:Guggenheim SMID Cap Biotech Conference in New York, NY with a fireside chat on Thursday, February 6, 2025 , at 10:30 a.m. ETin with a fireside chat on , at Citi's 2025 Virtual Oncology Leadership Summit with a fireside chat on Wednesday, February 19, 2025 , at 9:00 a.m. ETA live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.About SyndaxSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor

PR Newswire
Jan 15th, 2025
Incyte And Syndax Announce U.S. Food And Drug Administration (Fda) Approval Of Niktimvo™ (Axatilimab-Csfr) 9 Mg And 22 Mg Vial Sizes

– U.S. launch expected in early February –– Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis –– Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups –WILMINGTON, Del. and WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ -- Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies expect product to be available for order in the U.S

Stock Titan
Jan 7th, 2025
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Syndax announces presentation at 43rd Annual J.P. Morgan Healthcare Conference.